Gallate

Epigallocatechin-3-Gallate (EGCG): A Comprehensive Reference

1. Identity and Chemical Characterization

1.1 Nomenclature

Epigallocatechin gallate (EGCG), also known as epigallocatechin-3-gallate, is the ester of epigallocatechin and gallic acid, and is a type of catechin. Its systematic IUPAC name is (−)-epigallocatechin-3-O-gallate. The CAS registry number is 989-51-5. EGCG is a catechin compound with the molecular formula C₂₂H₁₈O₁₁ and a molecular weight of 458.372.

EGCG belongs to the subgroup of flavanols within the flavonoids family. It is the most thoroughly investigated member of the gallate class of catechins — a subgroup defined by possession of a galloyl (3,4,5-trihydroxybenzoyl) moiety esterified at the 3-position of the catechin skeleton. The pyrogallol-type structure on the B-ring induces apoptosis and possesses strong antioxidative activity, and the galloyl moiety (D-ring, gallate group) is the critical structure in the inhibition of fatty-acid synthase leading to cytotoxicity in human cancer cells.

1.2 Botanical Source

The natural product (−)-epigallocatechin-3-gallate (EGCG) is the major polyphenolic constituent found in green tea — dried fresh leaves of the plant Camellia sinensis L. Ktze. (Theaceae). Green tea belongs to the Theaceae family and is derived from two main varieties of Camellia sinensis: var. sinensis and var. assamica.

EGCG is found predominantly in green tea but also in a broad variety of foods, plants, and herbs, including cranberries, strawberries, blackberries, kiwis, cherries, pears, peaches, apples, avocados, pecans, pistachios, and hazelnuts. It is found in high content in the dried leaves of green tea (7,380 mg per 100 g), white tea (4,245 mg per 100 g), and in smaller quantities, black tea (936 mg per 100 g). During black tea production, the catechins are mostly converted to theaflavins and thearubigins via polyphenol oxidases.

The primary bioactive compounds found in green tea leaves are catechins, which make up 25% to 35% of the dry weight of the leaves. Several other polyphenolic compounds known as catechins are also found in lower abundance in green tea, including (−)-epicatechin-3-gallate (ECG), (−)-epigallocatechin (EGC), (−)-epicatechin (EC), and (+)-catechin. The dry extracts of green tea contain about 35% of polyphenols, 30% of which are due to catechins, which themselves contain 55–80% EGCG.

1.3 Common Forms and Preparations

EGCG is currently available as herbal drugs or green tea extracts (covered by monograph 1433 of the European Pharmacopoeia and monograph 2668 in Pharmeuropa), isolated or not. Tea beverages and capsules or tablets co-formulated with vitamins account for the main routes for EGCG intake. Commercially available supplements are typically standardized to defined percentages of EGCG, and the compound is also offered as isolated, high-purity powder. Like the other catechins, EGCG suffers from poor solubility and low skin permeability. The poor biopharmaceutical properties of EGCG are mainly due to its relatively low solubility in water, low chemical stability, low permeability, and a short plasma half-life.

2. Traditional and Historical Use

2.1 China

Use of the tea plant dates back to around 3000 BC in ancient China. Historical records, including the ancient medical text Shen Nong's Herbal Classic, demonstrate that the Chinese population was aware of tea's health-promoting and disease-preventative properties. For much of its early history in China, tea was consumed primarily as medicine rather than as a social beverage. TCM practitioners prescribed green tea for a range of conditions, including headaches and fatigue (attributed to the stimulating properties of caffeine), digestive complaints such as bloating, nausea, and diarrhea (attributed to tannins and catechins with astringent and antimicrobial properties), respiratory issues including chest congestion and coughs (attributed to theophylline as a natural bronchodilator), fevers and heat-related conditions (reflecting green tea's "cooling" classification in TCM), and as a general detoxifying agent to clear internal "dampness."

Before the Ming Dynasty (1368–1644), green tea was compressed into cakes. During the Ming period, loose-leaf tea culture emerged, forever changing how tea was brewed and enjoyed. In Traditional Chinese Medicine, green tea is classified as a cooling beverage, believed to reduce excess internal heat, making it particularly beneficial during warmer seasons or for inflammatory conditions.

2.2 Japan

When tea arrived in Japan in the 8th century via Chinese Buddhist monks, it carried its medicinal reputation. The Zen Buddhist priest Eisai (1141–1215), founder of the Rinzai school of Buddhism, brought tea seeds from China to plant in various places in Japan. Green tea was used in traditional medicine in Japan and China for a variety of purposes, from promoting digestive health to regulating blood sugar and wound healing. The Japanese tea ceremony (chanoyu) incorporated mindfulness, aesthetics, and social harmony alongside the health benefits of the tea itself. Today, Japan's approach to green tea reflects this holistic perspective: tea is consumed daily not as medicine per se, but as a foundational element of a healthy lifestyle.

2.3 Processing Methods in the Traditional Context

Traditional processing involves plucking bud leaves by hand, steaming (Japanese style) or pan-firing (Chinese style) within hours of harvest to halt oxidation. Teas made from unopened buds and early spring leaves contain especially high levels of EGCG. The preservation of catechin content — including EGCG — is a direct consequence of the minimal oxidative processing that characterizes green tea manufacture.

3. Key Constituents, Active Compounds, and Mechanisms of Action

3.1 Antioxidant Mechanisms

Studies have shown that the antioxidant effects of catechins, including EGCG, are more pronounced than those of vitamins C and E. EGCG has been shown to protect cells from ROS-induced damage caused by various agents, including hydrogen peroxide, primaquine, and iron. However, at high concentrations, EGCG can exhibit pro-oxidant activity by inducing autoxidation, which generates hydroxyl radicals, hydrogen peroxide, and quinone intermediates, leading to cytotoxicity. This dual behavior — antioxidant at physiological concentrations but potentially pro-oxidant at supraphysiological doses — is a critical pharmacological feature of the molecule.

Despite being a potent antioxidant, EGCG does not appear to act in vivo as a conventional hydrogen-donating antioxidant due to its low bioavailability. The circulating EGCG concentration is in the nanomolar interval, similar to hormones. Thus, rather than acting as a chemical antioxidant, in vivo EGCG likely generates signals for inducing protective enzymes and may exert modulatory actions in cells by acting as signaling molecules and/or regulating gene expression.

3.2 Anti-inflammatory Pathways

EGCG inhibits tumor necrosis factor-alpha (TNF-α)-mediated activation of the nuclear factor-kappa B (NF-κB) pathway, partly through inhibition of IκB kinase (IKK). EGCG markedly inhibits IL-1β-mediated IL-1β receptor-associated kinase (IRAK) degradation and the signaling events downstream from IRAK, including IKK activation, IκBα degradation, and NF-κB activation. In addition, EGCG inhibits phosphorylation of the p65 subunit of NF-κB.

In macrophage studies, EGCG inhibited accumulation of LPS-induced IL-12p40, IL-6, MCP-1, ICAM-1, and VCAM-1 mRNA, blocked LPS-induced IκBα degradation and RelA nuclear translocation, blocked the DNA-binding activity of NF-κB, and inhibited LPS-induced phosphorylation of ERK1/2, JNK, and p38.

3.3 Cell Signaling and Apoptosis

EGCG has demonstrated considerable therapeutic potential through modulation of key signaling pathways such as JAK/STAT, NF-κB, AKT, and Notch. This regulatory capacity governs essential cellular processes including apoptosis, proliferation, and survival. Much of the cancer chemopreventive properties of green tea are mediated by EGCG, which induces apoptosis and promotes cell growth arrest by altering the expression of cell cycle regulatory proteins, activating killer caspases, and suppressing oncogenic transcription factors and pluripotency maintenance factors.

In vitro studies have demonstrated that EGCG blocks carcinogenesis by affecting a wide array of signal transduction pathways including JAK/STAT, MAPK, PI3K/AKT, Wnt, and Notch. In muscle tissue, EGCG acts by modulating cell signaling including the NF-κB, AMP-activated protein kinase (AMPK), and mitogen-activated protein kinase (MAPK) signaling pathways, and through epigenetic mechanisms such as DNA methylation and histone acetylation.

3.4 AMPK Activation and Metabolic Pathways

EGCG increases hepatic autophagy by promoting the formation of autophagosomes, increasing lysosomal acidification, and stimulating autophagic flux in hepatic cells and in vivo. EGCG also increases phosphorylation of AMPK, one of the major regulators of autophagy; siRNA knockdown of AMPK abrogated autophagy induced by EGCG. Lipid droplets were observed within autophagosomes and autolysosomes, and EGCG increased lipid clearance, suggesting it promotes lipid metabolism by increasing autophagy.

3.5 Metal Chelation

EGCG is thought to promote neuroprotection by chelating transitional metals (iron and copper), inhibiting oxidative stress, and reducing inflammation, though much of the evidence comes from laboratory studies. The iron-chelating capacity of EGCG has additional implications for nutrient interactions (see Section 7).

4. Bioavailability and Pharmacokinetics

After oral administration, the bioavailability of EGCG was found to be very low in humans, resulting in plasma concentrations 5 to 50 times less than concentrations shown to exert biological activities in in vitro systems. Following oral administration, EGCG is rapidly absorbed, reaching peak plasma concentrations approximately one hour post-intake. The limited bioavailability of catechins may be attributed to significant gastrointestinal metabolism and hepatic extraction shortly after absorption. A pharmacokinetic study in healthy individuals receiving single doses of EGCG (ranging from 50 mg to 1,600 mg) revealed that plasma concentrations exceeded 1 μM only when doses of 1 g or higher were administered.

The direct absorption of EGCG is limited due to its low oral bioavailability, with a substantial portion reaching the colon where it interacts extensively with gut microbiota. This microbial interplay is crucial for EGCG's biotransformation and the realization of its health-promoting potential, yet the underlying mechanisms remain to be fully elucidated.

5. Scientific Evidence by Area of Use

5.1 Cardiovascular Health

A large cohort study carried out in Japan and published in JAMA in 2006 concluded that green tea consumption could be associated with reduced mortality due to cardiovascular disease. In a double-blind randomized controlled trial of 30 obese subjects, EGCG treatment (150 mg twice a day, orally) for 8 weeks significantly decreased systolic blood pressure, diastolic blood pressure, and mean arterial pressure (p<0.05 for all). EGCG treatment also increased the low-frequency to high-frequency power ratio (LF/HF ratio), indicating a shift toward sympathetic dominance.

A clinical study demonstrated that administration of green tea extract decreases the bioavailability of folic acid. In addition, clinical studies have confirmed EGCG's beneficial effects on metabolic disorders, endothelial dysfunction, and adverse cardiac remodeling. The overall body of cardiovascular evidence is encouraging but remains incomplete; large-scale randomized trials with hard cardiovascular endpoints are limited.

5.2 Cancer Chemoprevention

Laboratory experiments have provided evidence that epigallocatechin-3-gallate modulates numerous molecular targets and inhibits the pathogenesis of cancer through inhibition of initiation, promotion, and progression. However, clinical human trial-based studies are still needed to establish the efficacy of epigallocatechin-3-gallate in the management of cancer.

Various clinical trials on human subjects have examined whether EGCG plays a role in cancer prevention. In a placebo-controlled, randomized clinical trial of Polyphenon E (a mixture of green tea catechins containing 400 mg epigallocatechin-3-gallate per day), conducted on 97 men with high-grade prostatic intraepithelial neoplasia and/or atypical small acinar proliferation, with the primary endpoint being the cumulative one-year prostate cancer rate, no differences in the number of prostate cancer cases were seen.

Clinical trials in people with increased risk of cancer have not found preventive benefits of EGCG. The anti-tumor effects of EGCG are partially related to its wide anti-inflammatory and antioxidant effects, as EGCG may suppress chronic inflammatory processes resulting in cell transformation and hyperproliferation and initiation of carcinogenesis. Despite a large body of preclinical data, direct clinical evidence for cancer prevention remains preliminary and inconclusive.

5.3 Obesity and Body Composition

Clinical studies investigating EGCG intervention for obesity and non-alcoholic fatty liver disease (NAFLD) have utilized daily doses ranging from 150 mg to 900 mg. While many clinical studies have demonstrated that EGCG is associated with positive effects on various health parameters, including metabolic biomarkers, waist circumference, and body weight when consumed by individuals affected by obesity and NAFLD, there are also some reports suggesting that it may entail some degree of hepatotoxicity.

EGCG increases muscle lipid oxidation and stimulates glucose uptake in insulin-resistant skeletal muscle. EGCG works by increasing the expression of antioxidant enzymes, by reversing the increase of reactive oxygen species (ROS) production in skeletal muscle, and by regulating mitochondria-involved autophagy. Evidence in human subjects for sustained weight loss effects remains mixed and is characterized by generally modest effect sizes.

5.4 Non-Alcoholic Fatty Liver Disease (NAFLD)

EGCG has been proven to be effective against NAFLD in animal studies, ameliorating NAFLD phenotypes and metabolic disorders in rats fed a high-fat diet, and inhibiting intestinal barrier dysfunction and inflammation. Moreover, EGCG could restore gut microbiota diversity and composition, particularly promoting beneficial microbes including short-chain fatty acid producers such as Lactobacillus, and suppressing Gram-negative bacteria such as Desulfovibrio. In NAFLD patients, there is only relatively weak evidence suggesting the potential beneficial effects of EGCG on hepatic fat and aminotransferase levels, with these results primarily coming from inconsistent, small-scale studies that lack corresponding large-scale validation.

5.5 Neurodegeneration and Cognitive Function

Two small trials suggest that EGCG treatment may very modestly improve memory functions, inhibitory control, and adaptive behavior in people with Down syndrome, though this protective effect was evident in only 3 out of 24 cognitive tests. A three-month treatment of green tea extract (45% EGCG, 9 mg/kg/day EGCG) improved performance on a subset of measures on a battery of cognitive tests, including visual recognition memory. A subsequent randomized, placebo-controlled, double-blind study administered the same supplement (or placebo) to individuals with Down syndrome in combination with cognitive training for 12 months, with follow-up testing 6 months after treatment ended. The EGCG group displayed significantly higher scores in two of the 15 measures of the battery of cognitive tests (visual recognition immediate memory; inhibitory control) and in one of nine measures of adaptive behavior.

Two clinical trials in multiple sclerosis have reported that long-term EGCG treatment failed to improve brain health, measured by brain lesion volume and brain volume changes. In healthy adults, a single dose of EGCG has little influence on cognition. Despite promising results from in vitro and in vivo studies, there is still a translational gap between preclinical and clinical studies with EGCG in neurodegenerative disease treatment. Administration of 300 mg EGCG was associated with reduced stress, increased calmness, and increased electroencephalographic activity in midline frontal and central brain regions.

More than 60 trials on various EGCG extracts and formulations have been conducted or are ongoing, the majority on various types of cancer. The effects of EGCG or EGCG-containing green tea extracts have been assessed in over 100 clinical trials in a wide range of diseases and disorders that represent diverse underlying etiologies.

5.6 Glucose Metabolism and Type 2 Diabetes

In studies of cultured pancreatic β-cells, EGCG improves insulin secretion and mitochondrial activity. EGCG increases muscle lipid oxidation and stimulates glucose uptake in insulin-resistant skeletal muscle. Human clinical evidence for glycemic effects remains limited and does not yet allow strong conclusions; most evidence derives from animal or cell-based models.

5.7 Gut Microbiota and Intestinal Health

EGCG, the most abundant and bioactive catechin in green tea, is renowned for its potent biological activities. However, the direct absorption of EGCG is limited due to its low oral bioavailability, with a substantial portion reaching the colon where it interacts extensively with gut microbiota. EGCG's structural features as a flavan-3-ol with a polyphenolic structure containing multiple hydroxyl groups are central to its roles in gut health and systemic effects. While mechanistic data are accumulating, robust human clinical trials specifically examining gut microbiome endpoints remain scarce.

5.8 Skin and Photoprotection

Topical treatments with EGCG have been found to decrease the skin inflammatory response due to sun exposure by inhibiting inflammatory leukocyte infiltration and prostaglandin metabolite production. In addition, EGCG has been reported to protect against sunlight-induced suppression of the cutaneous immune system and to prevent photo-aging of the skin by reducing the expression of matrix metalloproteinases triggered by solar UV radiation. These findings derive predominantly from preclinical studies; human topical trials are limited.

6. Body Systems Associated with EGCG Activity

• Cardiovascular system: Potential health benefits include improving cardiovascular health.
• Metabolic/endocrine system: Emerging evidence underscores EGCG's therapeutic potential in preventing and managing a range of chronic conditions, including metabolic syndromes.
• Gastrointestinal system and hepatic function: EGCG has been shown to have anti-inflammatory, anti-cancer, and anti-steatotic effects on the liver.
• Nervous system: EGCG modulates key signaling pathways such as JAK/STAT, Delta-Notch, and TNF, all of which play critical roles in neuronal survival, growth, and function.
• Immune system: EGCG's ability to modulate cell signaling pathways associated with oxidative stress, apoptosis, and immune regulation highlights its multifaceted role in health promotion.
• Integumentary system (skin): Evidence from preclinical studies indicates antiphotoaging effects via matrix metalloproteinase suppression.
• Musculoskeletal system: EGCG works by increasing the expression of antioxidant enzymes, by reversing the increase of ROS production in skeletal muscle, and by regulating mitochondria-involved autophagy.

7. Dosage Forms and Reported Dosages in Studies

EGCG was reported safe and well tolerated in healthy humans at doses up to 800 mg/day administered orally for 4 weeks. Clinical studies investigating EGCG intervention for obesity and NAFLD have utilized daily doses ranging from 150 mg to 900 mg. In a double-blind randomized controlled trial of 30 obese subjects, EGCG was administered at 150 mg twice a day (300 mg total daily) orally for 8 weeks.

In a placebo-controlled randomized clinical trial in men with high-grade prostatic intraepithelial neoplasia, the intervention used a mixture of green tea catechins containing 400 mg epigallocatechin-3-gallate per day. In the Down syndrome pilot trial, the green tea extract providing 9 mg/kg/day of EGCG was administered for 3 months. A pharmacokinetic study in healthy individuals used single doses of EGCG ranging from 50 mg to 1,600 mg.

Dosage forms reported in the literature and pharmacopeias include:

• Oral capsules and tablets containing standardized green tea extract or isolated EGCG.
• Brewed tea infusion (the traditional and most common form of intake).
• Powdered extracts for dissolution in water.
• EGCG is covered by monograph 1433 of the current European Pharmacopoeia and monograph 2668 of Pharmeuropa.

Daily intake of 1,315 mg of green tea catechins containing 843 mg EGCG poses mainly mild, transient hepatic adverse effects.

8. Safety Considerations and Known Interactions

8.1 Hepatotoxicity

Green tea extract has been assigned a LiverTox® likelihood score of A (well established cause of clinically apparent liver injury). Preclinical and human data implicate the catechin component of green tea as the culprit of hepatotoxicity; of these catechins, epigallocatechin-3-gallate (EGCG) is present in the highest concentration.

The literature supports a potential relationship between high-dose green tea extract consumption and transient changes in serum liver enzymes. Rare (<5%) and transient liver transaminase elevations have been documented. Hepatotoxicity tended to show a temporal relationship with green tea extract consumption, with toxicity mainly manifesting after roughly 3–4 months of consumption.

Green tea extract and its principal component EGCG have been reported to have a "fat-burning" weight loss effect, which makes them among the most popular herbal and dietary supplements in the world. However, in contrast to these health benefits, the number of drug-induced liver injury (DILI) cases when GTE is used for weight loss has consistently increased, with GTE being the leading cause of herbal and dietary supplement DILI in the United States. GTE accounts for more than 50% of the suspected herbal and dietary supplement products that cause DILI. In severe cases, there is risk of acute liver failure or mortality.

One study observed for the first time that 400 mg/kg EGCG (equivalent to four times the common daily dose) could cause significant increase of transaminase and hepatocyte damage in a dietary restriction mouse model; however, in normal mice, the same dose of EGCG did not cause liver injury. These results suggested that dieting could increase the risk of EGCG-induced liver injury.

The close association of liver injury from green tea with the HLA allele B*35:01 suggests an immunologic etiology in at least a subset of cases, consistent with an idiosyncratic rather than purely dose-dependent mechanism.

There is great variability in the concentration of green tea extract, EGCG, and other components among marketed products, which may explain why some products have been implicated in hepatotoxicity.

8.2 Pro-oxidant Activity at High Concentrations

Exposure of rat hepatocytes to EGCG has been shown to induce mitochondrial toxicity and generation of reactive oxygen species. At high concentrations, EGCG can exhibit pro-oxidant activity by inducing autoxidation, which generates hydroxyl radicals, hydrogen peroxide, and quinone intermediates, leading to cytotoxicity.

8.3 Folate Interaction

The bioactive compounds in tea can interfere with the absorption of various molecules. An interaction with the folate transporter has been reported, leading to reduced bioavailability of folic acid. Therefore, it is advised that pregnant women, individuals with megaloblastic anemia, or those for whom folic acid reduction may have clinical consequences avoid the concurrent consumption of green tea and folic acid.

EGCG significantly reduces the concentration of 5-methyltetrahydrofolate (5-MTHF) in both solution and serum. However, the pro-degradation effect of EGCG on 5-MTHF can be reversed by L-ascorbic acid (AA). Subsequent investigations suggest that EGCG could potentially accelerate the degradation of 5-MTHF by generating hydrogen peroxide.

8.4 Iron Chelation and Mineral Interactions

Beyond iron, the strong binding affinity of tea polyphenols to proteins and minerals, such as calcium, magnesium, and folic acid, raises concerns regarding broader nutritional interactions. While evidence in humans remains limited, experimental studies indicate that tea polyphenols can reduce the bioavailability of folic acid and, in animal models, transiently decrease calcium absorption. In two clinical studies assessing specific metabolic routes or transporters, a proprietary EGCG formulation was found to have no effect on iron absorption, while a green tea extract formulation resulted in reduced bioavailability of co-administered folic acid.

8.5 Drug Interactions

One proposed mechanism for a documented drug interaction involves the inhibition of OATP1A2-mediated nadolol uptake. Green tea catechins have been shown in some studies to influence cytochrome P450 enzyme activity, though the clinical relevance of these observations varies and requires further evaluation in controlled studies.

8.6 Bioavailability Challenges as a Safety Context

EGCG has been shown to regulate dozens of disease-specific molecular targets. Many of these molecular targets are only affected by concentrations of EGCG that are far above the levels achieved by either drinking green tea or consuming moderate doses of green tea extract-based dietary supplements. This gap between effective in vitro concentrations and achievable in vivo plasma concentrations is a recurring limitation in the field and also partially explains the limited toxicity observed at beverage-equivalent doses.

8.7 Evidence Strength Summary

The impression from the published literature is that EGCG could prevent or even cure almost every disease; however, basic research provides clear support only for hypotheses on the use of EGCG, and an apparent discrepancy between those results and the occurrence of awaited effects in clinical trials remains. The overall state of evidence as of the most recent systematic reviews can be characterized as follows:

• Antioxidant and anti-inflammatory activity: Well-established in vitro and in preclinical models; confirmed in principle in human pharmacokinetic studies but limited by low bioavailability.
• Cardiovascular effects (cholesterol, blood pressure): Some positive signals from small randomized controlled trials; larger-scale confirmatory trials lacking.
• Cancer chemoprevention: Extensive preclinical evidence; human trials to date have been largely negative or inconclusive, particularly in prostate and other cancer types.
• Obesity/NAFLD: Mixed evidence in humans; some positive metabolic biomarker data but effect sizes are modest and long-term safety data incomplete.
• Neurocognitive effects: Some cognitive benefits are seen with EGCG in Down syndrome patients. Two trials in multiple sclerosis failed to show benefit. Long-term cognitive effects of EGCG in healthy adults are unknown.
• Hepatotoxicity risk: Well documented; GTE is the leading cause of herbal and dietary supplement drug-induced liver injury in the United States.

References

• Wang et al. (2006). Epigallocatechin-3-gallate (EGCG): Chemical and biomedical perspectives. PMC / Phytochemistry.
• Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential. PMC / MDPI Molecules, 2025.
• Epigallocatechin Gallate – Overview. ScienceDirect Topics.
• Epigallocatechin gallate. Wikipedia.
• Tea Polyphenol Epigallocatechin Gallate and the Gut-Health Axis. PubMed, 2025.
• Potential Therapeutic Targets of EGCG in Various Types of Cancer. PMC, 2020.
• EGCG – Cognitive Vitality for Researchers. Alzheimer's Drug Discovery Foundation.
• EGCG & Your Brain. Cognitive Vitality, Alzheimer's Drug Discovery Foundation.
• Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls Than Promises? PubMed, 2011.
• Green Tea – LiverTox®. NIH/NCBI Bookshelf.
• Epigallocatechin Gallate During Dietary Restriction — Potential Mechanisms of Enhanced Liver Injury. Frontiers in Pharmacology, 2020.
• Hepatotoxicity of High Oral Dose (−)-Epigallocatechin-3-Gallate in Mice. PMC / Toxicological Sciences, 2010.
• Repeated Dose Studies with Pure Epigallocatechin-3-gallate Demonstrated Dose and Route Dependent Hepatotoxicity. PMC, 2017.
• The Safety and Efficacy of Dietary EGCG Supplementation for Obesity and NAFLD: Recent Updates. PMC, 2025.
• EGCG Modulates Muscle Homeostasis in Type 2 Diabetes and Obesity. PMC / Antioxidants, 2019.
• Therapeutic Effects of EGCG in Relation to Inflammation, Oxidative Stress, and Apoptosis. PMC, 2023.
• Green Tea Catechin EGCG: Mechanisms, Perspectives and Clinical Applications. PMC, 2014.
• Epigallocatechin-3-gallate Inhibits LPS-Induced NF-κB and MAPK Signaling Pathways in Macrophages. PMC, 2012.
• EGCG, a Green Tea Polyphenol, Stimulates Hepatic Autophagy and Lipid Clearance. PubMed, 2014.
• EGCG Protects Against NAFLD and Associated Endotoxemia in Rats. PubMed, 2024.
• The Efficacy of EGCG in the Treatment of Alzheimer's Disease. PMC, 2017.
• Evaluation of the Therapeutic Potential of EGCG via Oral Gavage in Down Syndrome Mice. PMC / Scientific Reports, 2020.
• Scientific Opinion on the Safety of Green Tea Catechins (EFSA). PMC, 2020.
• Green Tea: Current Knowledge and Issues. PMC, 2025.
• Catechins and Human Health: Breakthroughs from Clinical Trials. PMC, 2025.
• Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential. MDPI Molecules, 2025.
• A Teacupful of Medicine? Nature Structural & Molecular Biology, 2008.
• EGCG Induces Degradation of Active Folate in Serum via H₂O₂ Generation. ScienceDirect, 2024.
• Iron Chelation Properties of EGCG in Colorectal Cancer Cells. PMC / Evidence-Based Complementary and Alternative Medicine, 2020.
• EGCG Inhibits IL-1β–Dependent Proinflammatory Signal Transduction in Respiratory Epithelial Cells. PubMed, 2004.